



Drug Delivery for Treatment of Neurodegenerative Diseases

Guest Editors:

Prof. Dr. Antonio Di Stefano

Department of Pharmacy,
University G. d'Annunzio, Via dei
Vestini, 66100 Chieti, Italy

Dr. Lisa Marinelli

Department of Pharmacy, "G.
d'Annunzio" University of Chieti-
Pescara, 66100 Chieti, Italy

Deadline for manuscript
submissions:

closed (30 April 2020)

Message from the Guest Editors

Dear Colleagues,

The failure of many molecules as CNS pharmacologically active compounds is due to different restrictions, such as poor water solubility, reduced intestinal absorption, in vivo stability, bioavailability, plasma fluctuation levels, and difficulties crossing the blood–brain barrier (BBB). Nanotechnology-based approaches, employing liposomes, micelles, dendrimers, and solid lipid nanoparticles (SLN) as drug delivery systems, are used to overcome the above-reported limitations. During the last few decades, new drug delivery technologies have emerged to treat neurodegenerative diseases; these formulations have the ability to protect drugs from chemical and enzymatic degradation, deliver the active compound to the target site with a substantial reduction of systemic toxicity, and pass physiological barriers, increasing bioavailability without resorting to high dosage forms. The aim of this Special Issue is to highlight current progress in the use of new drug delivery technologies to overcome the BBB and to target drugs to the CNS.

Prof. Antonio Di Stefano

Dr. Lisa Marinelli

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma